Product Description
Eflornithine administered by injection is used to treat African sleeping sickness, a disease caused by protozoa (tiny one-celled animals). However, eflornithine hydrochloride applied topically as a cream is the first agent known to help slow the rate of excessive hair growth. It is marketed under the brand name Vaniqa® and comes as eflornithine hydrochloride 13.9% cream. Eflornithine works by blocking the enzyme ornithine decarboxylase (ODC) that stimulates hair growth. (Sourced from: https://dermnetnz.org/topics/eflornithine-hydrochloride)
Mechanisms of Action: ODC Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Croatia | Czech | Denmark | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Jordan | Latvia | Lebanon | Lithuania | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Romania | Slovakia | Spain | Sweden | Switzerland | Turkey | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Panbela Therapeutics
Company Location:
Company CEO: Jennifer K. Simpson
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 7
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Astrocytoma
Phase 2: Brain Cancer|Breast Cancer|Glioma|Melanoma|Neuroblastoma|Osteosarcoma|Primitive Neuroectodermal Tumors|Rhabdoid Tumor|Sarcoma, Ewing|Skin Cancer|Type 1 Diabetes
Phase 1: Glioblastoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05879367 |
OT-21-101 | P1 |
Recruiting |
Glioblastoma|Astrocytoma |
2026-06-30 |
50% |
2025-06-26 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT06465199 |
BCC020 | P2 |
Recruiting |
Brain Cancer|Rhabdoid Tumor|Osteosarcoma|Glioma|Primitive Neuroectodermal Tumors|Sarcoma, Ewing|Neuroblastoma |
2033-02-01 |
12% |
2025-12-11 |
Primary Endpoints |
NCT07321912 |
BCC023 | P2 |
Not yet recruiting |
Sarcoma, Ewing|Osteosarcoma |
2031-04-01 |
12% |
2026-01-08 |
Primary Endpoints|Treatments |
NCT07287917 |
AMXT1501-103 | P2 |
Recruiting |
Melanoma|Breast Cancer|Skin Cancer |
2028-02-28 |
12% |
2025-12-18 |
Primary Endpoints|Treatments |
NCT05594563 |
TADPOL | P2 |
Recruiting |
Type 1 Diabetes |
2027-12-01 |
2% |
2023-04-29 |
Primary Endpoints|Start Date |
NCT02139397 |
NMTRC010 | P2 |
Completed |
Neuroblastoma |
2024-01-19 |
30% |
2024-04-26 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
2016-000089-45 |
STELLAR Study | P3 |
Completed |
Astrocytoma |
2024-02-27 |
2025-07-09 |
Treatments |